New York-based AI healthcare startup Forus has raised $150 million in a Series C funding round led by Bain Capital Ventures, valuing the company at $3 billion. This represents a rapid valuation increase from four months prior, when the company was valued at approximately $1 billion. Forus, which previously operated as Tandem, uses AI agents to automate prescription-to-treatment workflows across all 50 US states. The company plans to use the capital to expand into additional medical specialties.
Forus Series C funding round
- ▪The Series C funding round for Forus included participation from Thrive Capital, General Catalyst, Accel, Redpoint Ventures, BoxGroup, and Pear VC.
- ▪The $150 million Series C round brings the total funding raised by Forus to over $300 million.
- ▪New York-based AI healthcare startup Forus raised $150 million in a Series C funding round led by Bain Capital Ventures.
AI-powered prescription workflow automation
- ▪Forus deploys AI agents to automate the prescription-to-treatment workflow, including insurance prior authorizations, copay assistance programs, and specialty pharmacy coordination.
- ▪The Forus prescription automation platform operates at no cost to healthcare providers or patients.
- ▪The Forus platform is live across all 50 US states and reaches patients in 85% of residential ZIP codes.
Biopharmaceutical partnership revenue model
- ▪Forus generates revenue through partnerships with biopharmaceutical companies rather than charging patients or healthcare providers.
- ▪Forus has established partnerships with nine of the world's 15 largest biopharmaceutical companies.
Rapid valuation growth
- ▪The September 2026 Series C funding round values Forus at $3 billion, which is approximately triple its valuation from four months prior.
- ▪In May 2026, Forus, then operating under the name Tandem, raised over $160 million in a Series B funding round.
Market positioning strategy
- ▪Forus plans to use the newly raised Series C capital to expand its AI-powered platform into additional medical specialties.
- ▪Forus raised back-to-back funding rounds of $160 million in May 2026 and $150 million in September 2026 to secure its market position.
Debatable claims
- ▪AI automation of prior authorizations improves patient health outcomes
- ▪Forus's biopharma-funded model compromises patient care neutrality
Story comments
Loading comments…